Fang - Pulmonary HTN Dueto Left Heart Disease...3 When to Suspect PVH Robbins IM, et al. CircHF 2013...
15
1 Pulmonary Hypertension Due to Left Heart Disease Diagnosis and Management James C. Fang, MD University of Utah Health Sciences Salt Lake City, UT Pulmonary Hypertension Some definitions ISHLT 2012;31:913–33
Transcript of Fang - Pulmonary HTN Dueto Left Heart Disease...3 When to Suspect PVH Robbins IM, et al. CircHF 2013...
1
Pulmonary Hypertension Due to Left Heart DiseaseDiagnosis and Management
James C. Fang, MD
University of Utah Health Sciences
Salt Lake City, UT
Pulmonary HypertensionSome definitions
ISHLT 2012;31:913–33
2
Pathophysiology of PH-LHD
Moraes, Colucci, Givertz Circulation 2000
Highest risk associated with
PVR >4 Wood units
PAsys >35 mmHg
PCW >25 mmHg
PAC <2.0 cc/mmHg
‘Mixed’ Pulmonary Hypertension in Heart Failure
Miller WL, et al. JACC-HF 2013
3
When to Suspect PVH
Robbins IM, et al. CircHF 2013
RAP <1546/207 (22%) PCW >15 after 0.5L NS over 5-10”
PH suspected by history and exam
PH on echocardiography
1) Age > 60 years?2) Comorbidities (DM, HTN, CAD, obesity)3) Valvular heart disease?4) LV systolic dysfunction?5) Echo abnormalities (LAE, LVH, or significant DD)6) BNP markedly elevated?
PAH Probable PH from LHD
All no 1-2 yes
PH from LHD
≥3 yes
ISHLT 2012;31:913–33
4
PA Pressures by DE and RHCPoor correlation
Fisher MR, Forfia P, et al. AJRCCM 2009
Sharifov OF, et al. JAHA 2016
“E/e’ had poor to mediocre linear correlation with LVFP”
5
PH secondary to LHDPathophysiology
ISHLT 2012;31:913–33
B
Ryan JJ, et al. AHJ 2012
20 mmHg
10 mmHg
50
16
20 mmHg
10 mmHg
6
PCW may not = LVEDP
Halperin and Taichman, Chest 2009
Of the 4320 with PH,580 (15%) had PCW<15,But310 (54%) of them had EDP>15
Particularly when1)PVR >32)PH was indication
N=11.523 mPA => 4320 (37%)
Bland-Altman limits of agreement, -15.2 to 9.5 mm Hg
EL Brittain, et al. PLoS ONE 8(10): e76461
PA Diastolic Pressure GradientPAD - PCW
7
PH at catheterization
1) LVEDP >18 mmHg?2) PCW > 15 mmHg?3) LAP >15 mmHg?
no yes
PH from LHD1) Exercise2) Leg lift3) Volume challenge4) Nitric oxide
Consider Vasodilator challenge<18 mmHg
PAH
>24 mmHg
PH from LHD
PH suspected by history and exam
18-24 mmHg
Intermediate Group
ISHLT 2012;31:913–33
Systolic PA Pressure and PVRLimitations
• Does not entirely describe afterload on RV
• PA compliance not accounted for
• Does not directly describe RV performance
• Has not emerged as predictor of RVF post LVAD in multivariate models
• PVR is calculated measure
• Low PASP is very late stage of RVF
8
Pulmonary Artery Pulsatility Index
Kang et al., JHLT 2015
OR 95%CIOn inotropes 0.21 0.02-0.97Off inotropes 0.49 0.01-1.94
>2.0
9
E
Tedford R, et al. Circulation 2012
PA 55/20/33PCW 10CO 5.0PVR 4.6 (=0.33 mmHg-s-mL-1)
VADs decrease pulmonary hypertension in HFREF
0
10
20
30
40
50
60
70
PA sys PA mean PCW CO PVR
Baseline Testing 3 days 6 wks
Zimpfer D, et al. JTCS 2007;133:689-695
N = 3527 continuous flow pump24 bridged to transplant210 +/- 83 days
10
Agent PVR PAm PCW CI SVR Notes
Nitroprusside 36% 23% 27% 30% 31% Titrated in 25-50 mcg/min increments
Milrinone 31% 12% 16% 42% 30% 50 mcg/kg iv bolus
Nitric Oxide 47% NC 24% 9% NC 80 ppm over 10 minutes
Prostaglandin E1
47% 21% 13% 23% 31% Titrated in doses of 0.02, 0.05, 0.10, 0.20, 0.30
mcg/kg/min
Adenosine 41% NC 12% 9% NC 100 mcg/kg/min
ISHLT 2012;31:913–33
PH, LVAD, and Sildenafil
Tedford RJ, et al. Circulation – HF 2008
11
RELAX trialPDE5i in HFpEF
Redfield MM, et al. JAMA 2013
PAH specific drugs in PH-LHDTrials and tribulations
Drug Trial Patients Endpoint Outcome
Epoprostenol FIRST 471 ACM Neutral
Tezosentan RITZ-1 669 Dyspnea Neutral
Bosentan ENABLE 1613 ACM/HFH Neutral
Darusentan EARTH-2 642 LVESVI Neutral
Milrinone PROMISE 1088 ACM Neutral
Enoximone ESSENTIAL 1854 ACM/CVH Neutral
PDE5i PITCH-HF xxxx CVD/HFH Suspended
ISHLT 2012;31:913–33
12
Nitric Oxide, PVR, and PCW
Loh E, et al. Circulation 1994
Inhaled Nitrites for HFpEF
Borlaug B, et al. Circulation Research 2016
13
Stasch JP, et al. Circulation 2011
LEPHT study - RiociguatSoluble guanylate cyclase stimulator
Bonderman D, et al. Circulation 2013
14
Haddad, F. et al. Circulation 2008
RVSWI (mmHg-ml/m2) = (mPAP – mCVP) x CI/HR
Summary
• PH in LHD should always be distinguished from PAH
• Treatment starts with establishing euvolemia
• PH specific drugs have yet to improve outcomes
• New paradigms are being sought
15
